Clinical trial
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent…
NCT00271323 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00271323 |
|---|---|
| Title | Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients |
| Official title | A Two Arm Phase II Study Assessing Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-multiple cN2 or IIIB) |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug, Radiation |
| Interventions | docetaxel and cisplatin, radiotherapy |
| Enrollment | 14 |
| Start date | May 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Dec 30, 2005 |
| Last update posted | Dec 23, 2009 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: